Coward et al reported the therapeutic effect of siltuximab (anti-IL-6 antibody) was accompanied by reductions in angiogenesis in ovarian cancer cells xenograft models (Coward et al., 2011). The gene discussed is IL6; the disease is ovarian carcinoma.